Postmarketing Surveillance Study of Berotec® N 100 µg Metered-dose Inhaler in Chronic Obstructive Respiratory Tract Disease

Boehringer Ingelheim

Status: Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Treatments: Drug: Berotec® N 100 µg Metered-dose Inhaler

Study type: Observational

Funder types: Industry

Identifiers

NCT02244216

260.3178

Details and patient eligibility

About

Study to obtain data about changing from the chlorofluorocarbon (CFC) - containing Berotec® 200 µg metered - dose inhaler to the CFC - free Berotec® N 100 µg metered - dose inhaler

Enrollment: 2,914 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients were included in the study only if they had been treated with Berotec® 200 µg metered - dose inhaler before switching to the CFC-free Berotec® N 100 µg metered - dose inhaler

Exclusion criteria

• Contraindications listed in the Instructions for Use/Summary of Product Characteristics for Berotec® N 100 µg metered - dose inhaler

Trial design

2,914 participants in 1 patient group

Chronic Obstructive Respiratory Tract Disease

Treatment:

Drug: Berotec® N 100 µg Metered-dose Inhaler